ACE2 News and Research

RSS

Study shows engineered antibodies significantly boost Omicron neutralization

Researchers engineered IgA antibodies from IgG monoclonals, enhancing neutralization against Omicron by up to 75-fold and offering protection in mice models.

10 Jan 2024

New Omicron subvariants test vaccine limits, reveal unique infection challenges

Study reveals that the Omicron subvariants BA.2.86 and FLip show unique mutations and infectivity profiles, with BA.2.86 being highly infectious and resistant to most conventional antibodies, underscoring the need for updated vaccines.

9 Jan 2024

Does SARS-CoV-2's ability to infect humans stem from its evolutionary past?

Study challenges the hypothesis of genetic recombination in SARS-CoV-2's evolution, suggesting its ancestral virus already possessed human-infecting traits, based on analyses of over 100 viral genomes.

7 Jan 2024

Study: High-fat diets impact genes in the intestines, brain, and immune system

A UC Riverside study to motivate your new year's resolutions: it demonstrates that high-fat diets affect genes linked not only to obesity, colon cancer and irritable bowels, but also to the immune system, brain function, and potentially COVID-19 risk.

3 Jan 2024

IFNγ identified as crucial for reducing pulmonary viral loads in COVID-19, new research shows

The role of type-2 interferon (IFNγ) in antiviral immunity.

14 Dec 2023

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants

Five DNA vaccine candidates based on different SARS-CoV-2 strains.

12 Dec 2023

New SARS-CoV-2 variant JN.1 shows increased transmissibility and immune resistance

A Japanese study published in BioRxiv explores the virological characteristics of the SARS-CoV-2 JN.1 variant, finding it has a higher effective reproductive number and stronger resistance to immunity from other variants, potentially due to the L455S spike protein mutation.

11 Dec 2023

Omicron infection linked to brain structure changes in men, study finds

Study reveals that men infected with the SARS-CoV-2 Omicron variant experience changes in brain structure, including reduced gray matter thickness and subcortical nuclear volume. These findings, based on MRI data and clinical symptoms, highlight the neurological impact of Omicron infection, contributing to our understanding of COVID-19's effects on the brain.

4 Dec 2023

Collaborative study focuses on understanding the strength of adhesion of COVID-19 variants

A recent groundbreaking study, published in Nature Nanotechnology, sheds new light on the coronavirus's behavior, particularly its ability to remain attached under various mechanical stresses and the implications for person-to-person transmission.

29 Nov 2023

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Study discovers that coffee, especially its bioactive compounds like chlorogenic acids, can inhibit SARS-CoV-2 entry and reduce ACE2 and TMPRSS2 levels, indicating that coffee intake might be a potential dietary strategy for COVID-19 prevention.

16 Nov 2023

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

In this study, researchers harnessed crowdsourcing and open science to develop new antivirals against SARS-CoV-2, focusing on its main protease, Mpro. Their approach led to the discovery of potent compounds, including one with high efficacy in cell lines and cross-reactivity against various COVID-19 variants, demonstrating the potential of collaborative and transparent drug discovery in tackling global health crises.

12 Nov 2023

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

In this groundbreaking study, researchers developed a mucosal adenoviral-vector vaccine, ChAd-SARS-CoV-2-S, which demonstrated sustained and robust immunity against a challenging Omicron variant in nonhuman primates, indicating a promising direction for durable COVID-19 protection strategies. Unlike traditional intramuscular vaccines, this mucosal vaccine elicited a comprehensive immune response, potentially paving the way for more effective and long-lasting COVID-19 vaccines.

9 Nov 2023

Omicron variant BA.2.86 spreads faster, but current antivirals hold the line

Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.

7 Nov 2023

New gene editing method creates first mice with human-like COVID-19

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

1 Nov 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

24 Oct 2023

Community immunity: Steering the evolutionary course of SARS-CoV-2

Researchers in Germany have developed a comprehensive fitness model that forecasts the evolution of SARS-CoV-2 by integrating genetic, epidemiological, and immunological data. The study emphasizes the role of population immunity in shaping viral mutations and provides valuable insights into the emergence of new variants.

24 Oct 2023

Engineered bacteria could offer new treatment for hypertension

Scientists at The University of Toledo have proven that engineered bacteria can lower blood pressure, a finding that opens new doors in the pursuit of harnessing our body's own microbiome to treat hypertension.

24 Oct 2023

Is COVID-19 a risk factor for Alzheimer's disease?

The study explores the interconnected risks between COVID-19 and Alzheimer's Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.

23 Oct 2023

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.

22 Oct 2023

ACE2 News and Research

Study shows engineered antibodies significantly boost Omicron neutralization

New Omicron subvariants test vaccine limits, reveal unique infection challenges

Does SARS-CoV-2's ability to infect humans stem from its evolutionary past?

Study: High-fat diets impact genes in the intestines, brain, and immune system

IFNγ identified as crucial for reducing pulmonary viral loads in COVID-19, new research shows

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants

New SARS-CoV-2 variant JN.1 shows increased transmissibility and immune resistance

Omicron infection linked to brain structure changes in men, study finds

Collaborative study focuses on understanding the strength of adhesion of COVID-19 variants

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

Omicron variant BA.2.86 spreads faster, but current antivirals hold the line

New gene editing method creates first mice with human-like COVID-19

NF-κB activation during COVID-19 and its impact on patients with hypertension

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Community immunity: Steering the evolutionary course of SARS-CoV-2

Engineered bacteria could offer new treatment for hypertension

Is COVID-19 a risk factor for Alzheimer's disease?

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News